Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma

M. Shirin Sabbaghian, Gary Rothberger, Alexandra P. Alongi, Jean Pierre Gagner, Judith D. Goldberg, Linda Rolnitzky, Luis Chiriboga, Cristina H. Hajdu, David Zagzag, Ross Basch, Peter Shamamian

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Aim: To evaluate circulating endothelial lineage cells (ELCs) as biomarkers of tumor neovascularization in patients with pancreatic ductal adenocarcinoma (PDAC). Materials and Methods: ELCs were isolated from the peripheral blood of patients with PDAC (n=14) or controls (n=17) before and after tumor resection/surgery and quantified using flow cytometry. Vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) were detected in tumor using immunohistochemistry and in plasma using an ELISA technique. Results: Circulating ELC levels were increased in patients with PDAC compared to controls. After PDAC resection, ELC levels declined. ELC level increases were associated with cancer recurrence. VEGF and PlGF were identified in cancer cells and exocrine pancreas cells. Only PlGF was detected in tumor-associated inflammatory cells. Plasma levels of PlGF were higher in patients with PDAC compared to controls. Conclusion: Circulating ELCs are a potential biomarker of PDAC neovascularization, and PlGF may be an important target in treatment of PDAC.

Original languageEnglish (US)
Pages (from-to)2911-2917
Number of pages7
JournalAnticancer Research
Volume30
Issue number7
Publication statusPublished - Jul 1 2010
Externally publishedYes

    Fingerprint

Keywords

  • Angiogenesis
  • Endothelial cells
  • Neovascularization
  • Pancreatic cancer
  • Placental growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sabbaghian, M. S., Rothberger, G., Alongi, A. P., Gagner, J. P., Goldberg, J. D., Rolnitzky, L., ... Shamamian, P. (2010). Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. Anticancer Research, 30(7), 2911-2917.